A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT02703272


The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival \[EFS\]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).

Official Title

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Stanford Investigator(s)


Inclusion Criteria:

* Participants with 1 to less than (\<) 18 years of age (Part 1 only), or 1 to 30 years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at \<18 years of age (Part 2 only)
* Participants must be in first recurrence and have received only one prior line of therapy or have disease that is primarily refractory to conventional therapy
* Participants must have at least 1 of the following: 1 site of measurable disease greater than (\>) 1 centimeter (cm) in the longest diameter and \>1 cm in the shortest diameter by radiological imaging; bone marrow involvement; cerebrospinal fluid with blasts present
* Participants with lansky-Karnofsky score of greater than or equal to (\>=) 50
* Adolescent women/young women of childbearing potential must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization. Adolescent/young women who are pregnant or breastfeeding are ineligible for this study

Exclusion Criteria:

* Participants with ongoing anticoagulation treatment with warfarin or equivalent vitamin K antagonists (example phenprocoumon), or ongoing treatment with agents known to be strong CYP3A4/5 inhibitors, or has taken any disallowed therapies as noted in Section 8.2, Prohibited Medications, before the planned first dose of study drug
* Participants with inherited or acquired bleeding disorders
* Participants with clinically significant arrhythmias, complex congenital heart disease, or left ventricular ejection fraction (LVEF) \<50 percent (%) or shortening fraction (SF) \<=28%
* Participants with known history of human immunodeficiency virus (HIV) or active Hepatitis B or C virus
* Participants with any condition that could interfere with the absorption or metabolism of ibrutinib including malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel
* Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)
* A diagnosis of post-transplant lymphoproliferative disease (PTLD)
* Participants who are within 6 months of an allogeneic bone marrow transplant
* Participants who have had prior exposure to ibrutinib


drug: Ibrutinib

drug: Rituximab

drug: Ifosfamide

drug: Carboplatin

drug: Etoposide

drug: Vincristine

drug: Idarubicin

drug: Dexamethasone

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott

New Trial Alerts